Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Apyx Medical (APYX) Research & Development (2016 - 2025)

Apyx Medical's Research & Development history spans 15 years, with the latest figure at $971000.0 for Q4 2025.

  • For Q4 2025, Research & Development fell 13.07% year-over-year to $971000.0; the TTM value through Dec 2025 reached $3.4 million, down 33.07%, while the annual FY2025 figure was $3.4 million, 33.07% down from the prior year.
  • Research & Development reached $971000.0 in Q4 2025 per APYX's latest filing, up from $801000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $1.4 million in Q2 2024 to a low of $801000.0 in Q3 2025.
  • Average Research & Development over 5 years is $1.1 million, with a median of $1.1 million recorded in 2024.
  • Peak YoY movement for Research & Development: skyrocketed 32.8% in 2023, then tumbled 42.45% in 2025.
  • A 5-year view of Research & Development shows it stood at $947000.0 in 2021, then surged by 32.52% to $1.3 million in 2022, then increased by 11.79% to $1.4 million in 2023, then fell by 20.38% to $1.1 million in 2024, then decreased by 13.07% to $971000.0 in 2025.
  • Per Business Quant, the three most recent readings for APYX's Research & Development are $971000.0 (Q4 2025), $801000.0 (Q3 2025), and $824000.0 (Q2 2025).